Financials Alumis Inc.

Equities

ALMS

US0223071020

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 06/07/2024 am IST 5-day change 1st Jan Change
11.45 USD -1.72% Intraday chart for Alumis Inc. -13.91% 0.00%

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023
Net sales - -
EBITDA 1 -113.6 -156.9
EBIT 1 -113.8 -158.2
Operating Margin - -
Earnings before Tax (EBT) 1 -111.9 -155
Net income 1 -111.9 -155
Net margin - -
EPS 2 -14.93 -15.42
Free Cash Flow - -80.5
FCF margin - -
FCF Conversion (EBITDA) - -
FCF Conversion (Net income) - -
Dividend per Share - -
Announcement Date 07/06/24 07/06/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023
Net Debt 1 - -
Net Cash position 1 91.1 16.4
Leverage (Debt/EBITDA) - -
Free Cash Flow - -80.5
ROE (net income / shareholders' equity) - -245%
ROA (Net income/ Total Assets) - -100%
Assets 1 - 155
Book Value Per Share 2 -26.00 -27.10
Cash Flow per Share 2 3.420 3.680
Capex 1 2.41 4.5
Capex / Sales - -
Announcement Date 07/06/24 07/06/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. ALMS Stock
  4. Financials Alumis Inc.